Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06541665
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-02
Brief Title:
Phase I Study Evaluating Tolerability Safety Pharmacokinetics and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicenter Phase I Open-label Uncontrolled Study of ONO-4059 in Combination With Rituximab Methotrexate Procarbazine and Vincristine R-MPV Therapy for Untreated Primary Central Nervous System Lymphoma PCNSL
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None